Roivant Sciences Ltd. ROIV
Deals with insiders in the proxy filed Jul 29, 2026
Proxy, Item 404Deals between ROIV and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Jul 29, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Jul 29, 2025.
Certain Employment and Compensatory Arrangements“Brett Venker, Vice President of Operations for our subsidiary, Covant, is the brother of Eric Venker, Roivant’s President and Immunovant CEO. During Fiscal 2025, Brett Venker earned total cash compensation, consisting of salary, bonus, non-equity incentive plan compensation and other compensation, of $407,093 and was granted incentive equity awards in the Company and a private subsidiary of the Company with an aggregate grant date fair value, as computed in accordance with Topic 718, of $589,551.”
Read it in the proxyopen_in_new
No longer reported 1 paragraph of the proxy filed Jul 29, 2025 with nothing like them this year
Transactions and Arrangements with Sumitomo Pharma Co., Ltd. (“Sumitomo”)“In March 2024, the Company’s Board of Directors authorized a common share repurchase program, allowing for repurchases of common shares in an aggregate amount of up to $1.5 billion (excluding fees and expenses). Pursuant to the share repurchase program, on April 2, 2024, the Company entered into a share repurchase agreement with Sumitomo to repurchase all 71,251,083 common shares held by Sumitomo at a purchase price per share of $9.10, for an aggregate purchase price of approximately $648.4 million. The repurchase transaction with Sumitomo was completed on April 2, 2024.”
Read it in last year's proxyopen_in_new
The whole section
As filed
8 paragraphs quoted as filed
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS“The following is a description of certain transactions occurring during our last fiscal year or currently proposed, including those to which (i) Roivant has been a participant, (ii) the amount involved exceeded or will exceed $120,000 and (iii) any of Roivant’s directors, executive officers or holders of more than 5% of Roivant’s share capital, or any members of their immediate family, had or will have a direct or indirect material interest.”
Read it in the proxyopen_in_new
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS“Other than as described below, there have not been, nor are there any currently proposed, transactions or series of similar transactions meeting these criteria to which we have been or will be a party other than compensation arrangements, which are described where required under the sections of this Proxy Statement entitled “Information About Roivant’s Directors” and “Executive Compensation.””
Read it in the proxyopen_in_new
Certain Employment and Compensatory Arrangements“Brett Venker, Vice President of Operations for our subsidiary, Covant, is the brother of Eric Venker, Roivant’s President and Immunovant CEO. During Fiscal 2025, Brett Venker earned total cash compensation, consisting of salary, bonus, non-equity incentive plan compensation and other compensation, of $407,093 and was granted incentive equity awards in the Company and a private subsidiary of the Company with an aggregate grant date fair value, as computed in accordance with Topic 718, of $589,551.”
Read it in the proxyopen_in_new
Related Person Transaction Policy“We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of Roivant’s voting securities, and any of their respective immediate family members and any entity owned or controlled by such persons.”
Read it in the proxyopen_in_new
Related Person Transaction Policy“Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our Audit Committee, or, if Audit Committee approval would be inappropriate, to another independent body of our Board of Directors, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant shareholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Conduct, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our Audit Committee, or other independent body of our Board of Directors, is required to take into account the relevant available facts and circumstances including, but not limited to:”
Read it in the proxyopen_in_new
Related Person Transaction Policy“the impact on a director’s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated;”
Read it in the proxyopen_in_new
Related Person Transaction Policy“the availability of other sources for comparable services or products; and the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.”
Read it in the proxyopen_in_new
Related Person Transaction Policy“The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our Audit Committee, or other independent body of our Board of Directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our Audit Committee, or other independent body of our Board of Directors, determines in the good faith exercise of its discretion.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.